Dr. Beth Jonas answers the question: 'Newer Vs. Older DMARDs for Rheumatoid?' — -- Question: How do the older DMARDs differ from the newer DMARDs and is either group of drugs better for the ...

How long do you need to take a disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis before it's fully effective? It depends on which one you use. But they all take a while, says Eric ...

DMARDs, including TNF-alpha inhibitors, may relieve pain and inflammation and help prevent joint damage from rheumatoid arthritis (RA). TNF-alpha inhibitors block TNF-alpha, which causes joint pain ...

A study conducted in Denmark showed that treatment of rheumatoid arthritis with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents ...

Psoriatic arthritis (PsA) is a long-term, inflammatory disease affecting the joints and where tendons and ligaments connect to the bones. It doesn't have a cure. But a growing number of treatments can ...

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints (those between the spine and hipbone). Less commonly, AS can affect other joints such ...

rheumatoid arthritis dmard vs biologic Updated American College of Rheumatology recommendations suggest using first-line DMARDs in combination with biologic agents and nonbiologic DMARDs to achieve ...

Please provide your email address to receive an email when new articles are posted on . Biologic disease-modifying antirheumatic drugs used to treat juvenile rheumatic diseases are excluded entirely ...

Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...

When the symptoms of psoriatic arthritis (PsA) are severe, doctors often turn to disease-modifying antirheumatic drugs (DMARDs) for treatment. These drugs alleviate the symptoms of psoriatic arthritis ...

While overall risks for adverse birth outcomes were not increased in children born to fathers who used disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, for autoimmune diseases in ...